



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>G01N 33/567, 33/487, C12Q 1/02, C12M 1/40</b>		A1	(11) International Publication Number: <b>WO 98/55870</b> (43) International Publication Date: 10 December 1998 (10.12.98)
(21) International Application Number: <b>PCT/SE98/01058</b> (22) International Filing Date: 3 June 1998 (03.06.98)  (30) Priority Data: 9702112-5                          4 June 1997 (04.06.97)                          SE		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant ( <i>for all designated States except US</i> ): A+ SCIENCE INVEST AB [SE/SE]; P.O. Box 3096, S-400 10 Göteborg (SE). (72) Inventors; and (75) Inventors/Applicants ( <i>for US only</i> ): ORWAR, Owe [SE/SE]; Vasagatan 35, S-411 37 Göteborg (SE). JARDEMARK, Kent [SE/SE]; Tigerstigen 5, S-426 72 V Frölunda (SE). (74) Agent: AWAPATENT AB; P.O. Box 11394, S-404 28 Göteborg (SE).		Published <i>With international search report.</i>	
<p><b>(54) Title:</b> DETECTION OF BIOLOGICALLY ACTIVE MOLECULES BY USE OF PRE-ACTIVATED CELL-BASED BIOSENSORS IN LIQUID-BASED SEPARATION SYSTEMS</p> <p style="text-align: center;"> <b>★ - Antagonist</b>  <b>☆ - Agonist</b> </p> <p><b>(57) Abstract</b></p> <p>The present invention relates to a method for detection of receptor antagonists comprising the following steps: (I) a sample containing the receptor antagonist is fractionated by use of a liquid-based separation means, preferably capillary electrophoresis; (II) a fraction containing the receptor antagonist is fed directly to a biosensor (9), preferably a living cell, activated by a receptor agonist and, as a result of this activation, is generating a measurable response, said agonist being fed to the biosensor through the liquid-based separation means together with the antagonist; and (III) the change of the response resulting from deactivation of the receptor agonist-activated biosensor by the receptor antagonist or modulator is measured, preferably by means of a patch clamp electrode (8). It is further possible to resensitise the biosensor desensitised as above by use of interlocked pulsed superfusion of the biosensor. The present invention also relates to an apparatus usable for practising the above mentioned method.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

DETECTION OF BIOLOGICALLY ACTIVE MOLECULES BY USE OF  
PRE-ACTIVATED CELL-BASED BIOSENSORS IN LIQUID-BASED  
SEPARATION SYSTEMS

Field of the invention

The present invention relates to a method and an apparatus for detection of endogenous and synthetic receptor antagonists and receptor modulators, such as e.g. 5 drugs and pharmaceutically active substances. More specifically, the present invention relates to a method and an apparatus based on the use of a miniaturised liquid-based separation technique coupled to a biosensor activated by a receptor agonist and thus giving rise to a 10 measurable response that is affected in a measurable way by the receptor antagonist to be detected.

Background of the invention

Biologically active compounds generally lack features enabling sensitive detection thereof by conventional techniques, and their roles in biochemical and physiological processes are therefore often difficult to elucidate. 15

The detection of biologically active compounds is of 20 particular interest in the pharmaceutical field, e.g. during development of new drugs. Since many native and synthetic substrates constituting commercial drugs act as inhibitors of dysfunctional events in the human body, it is of importance to find systems that enable screening or 25 detection of molecules with that mode of action.

In recent years, there has been an exponential increase in the number of compounds which are interesting for screening. Synthetic libraries from drug companies and natural products have been some of the sources of 30 these compounds. The compounds origin from a broad spectrum of different organisms, such as bacteria, insects, plants and marine organisms. This, together with the introduction of combinatorial libraries for the manufactur-

CONFIRMATION COPY

ing of several thousands of compounds have led to a great demand for new screening techniques which are faster and more selective than the ones used today. Known methods used for drug screening are generally based on pure  
5 chemical binding between compounds extracted from, for example, natural products and target molecules, such as receptors, enzymes or nucleic acids. The target molecules can also be included in biological systems, such as living cells, where the merits of chemical recognition and  
10 biological amplification are combined.

The use of specific target molecules for the evaluation of a compound's biological potential is based on the creation of systems of biological relevance for the analysed compound. Strategies in this field often include  
15 expression of cloned cDNA in different cell systems for the production of a functional target molecule in its natural environment.

There are also examples of screening systems which are based on cell effects where the response cannot be  
20 traced to a single target molecule.

Several different techniques are presently used for biological screening and characterisation of potential drugs, and some examples of these techniques are given below.

25       *Microphysiometry*: During the growth of a typical biological cell, carbon-containing nutrients such as glucose are taken up and acidic metabolic products such as lactic acid are released. In microphysiometry these changes in metabolic rate are recorded as changes in the  
30 rate of acidification of the medium surrounding the cells (see e.g. Raley-Susman, K. M., et al., J. Neurosci. 12:773, 1992; Baxter, G. T., et al., Biochemistry 31:10950, 1992; Bouvier, C., et al., J. Recept. Res. 13:559, 1993; and McConnell, H. M., et al., Science 35 257:1906, 1992). Virtually any molecule that affects the cell can be detected by this method. Such molecules include neurotransmitters, growth factors, cytokines and so

forth. The microphysiometry is unable to distinguish between different antagonists acting on the same receptor system and can therefore not be used for binary or more complex solutions of such agents. Other drawbacks of this 5 system are the low-level detection, measuring changes in pH is far less selective than measuring responses on the receptor level, and slow recovery rates.

*Immunoassays:* This group of techniques is based on in vitro procedures for screening of specific antigens 10 (see e.g. Tu, J., et al., Clin. Chem. 44:232, 1998; Pinilla, C., et al., Biomed. Pept. Proteins Nucleic Acids 1:199, 1995; Tawfik, D. S., et al., Proc. Natl. Acad. Sci. USA 90:373, 1993; and Houghten, R. A., et al., Bio-techniques 13:412, 1992). Antibodies, often immobilised, 15 are used as targets for antigens. The antigen-antibody interaction is detected by a second antibody, which is labelled by e.g. an radioactive isotope. The problems with these immuno-based techniques are related to the difficulties in raising specific antibodies for small 20 molecules that are identical or resemble endogenous compounds. Another problem is related to the handling of radioactive substances.

*Use of combinatorial libraries:* Synthetic combinatorial libraries have proven to be a valuable source of diverse structures useful for large-scale biochemical 25 screening (see e.g. Sastry, L., et al., Ciba Found Symp. 159:145, 1991; Huse, W., Ciba Found Symp. 159:91, 1991; Persson, M. A., et al., Proc. Natl. Acad. Sci. USA 88:2432, 1991; Kang, A. S., et al., Proc. Natl. Acad. 30 Sci. USA 88:4363, 1991; Houghten, R. A., et al., Nature 354:84, 1991; Clackson, T., et al., Nature 352:624, 1991; and Ostresh, J. M., et al., Proc. Natl. Acad. Sci. 35 91:11138, 1991). The libraries are generated by a combination of solution and solid-phase chemistries and are cleaved off the solid-support for screening. When mixtures of compounds are screened, however, the possibility

exists that the most active compound will not be identified.

*Separation techniques coupled to mass spectrometry:* Separation techniques such as liquid chromatography, gas chromatography and capillary electrophoresis coupled to mass spectrometry or tandem-mass spectrometry create analytical systems available for structure evaluation (see e.g. Hsieh, S., et al., Anal. Chem. 70:1847, 1998; Tretyakova, N. Y., et al., J. Mass. Spectrom. 33:363, 1998; Bonnichsen, R., et al., Zaccia 6:371, 1970; Taylor, G. W., et al., Br. J. Clin. Pharmacol. 42:119, 1996; and McComb, M. E., et al., J. Chromatogr. A 800:1, 1998). Mass spectrometry gives information about the molecular weight of the analysed molecule. With refined and controlled fragmentation of large molecules it is also possible to extract information about the sequence.

*Enzyme assays using proteases:* Many proteases have become targets for drug discovery (see e.g. Carroll, C. D., et al., Adv. Exp. Med. Biol. 436:375, 1998; Ferry, G., et al., Mol. Divers. 2:135, 1997; and Jiracek, J., et al., J. Biol. Chem. 270:21701, 1995), from viral proteases required for the generation of active viral proteins to mammalian proteases that process pro-hormones to their active mature forms. Assays have been developed in bacterial systems to screen for compounds that inhibit protease activity. Most of these involve the co-expression of both the protease and a target reporter gene (the gene that encoded the protein which creates a measurable effect) in the same cell. A number of in vitro biochemical assays have also been developed. In most of these cases, a peptide containing the protease cleavage site is labelled at one end using either a radioactive or a fluorescent tag. The other end of the peptide molecule is adhered to a plate or a bead. In the presence of an active protease, the peptide is cleaved and the labelled end is released. The loss of signal from the labelled end of the peptide molecule after washing reflects the activity of

the protease and can be easily monitored. For detection of protease inhibitor the grade of maintenance of the signal can instead be measured. These assays are, however, often time consuming since they involve genetic engineering.

A significant limitation of the above mentioned methods is the capacity; the number of compounds that can be rapidly evaluated is extremely low. Alternative methods for high through-put screens are needed.

Another major disadvantage of these known biological screening systems is that they involve extensive multi-step purification and isolation of the compounds which are to be tested.

Capillary-based separation methods for identifying bioactive analytes in a mixture have earlier been described in WO 96/10170 (PCT/US95/12444). The methods described herein is however not fully satisfying for detection of antagonists. In the application detection of antagonists is mentioned. However, it seems that the agonist needed for detection of antagonists is then either included in the bathing solution or fed to the cell by a second capillary or tube system. A major drawback with this solution is that the agonist would immediately dissipate from the surface of the cell-based biosensor when the separation process is started. This eliminates the effect of pre-activation which is necessary for accurate biosensor-detection of antagonists.

#### Summary of the invention

The disadvantages of the above mentioned methods for drug screening can be eliminated with the method according to the present invention.

The present invention provides methods and apparatus for detection of biologically active analytes separated by liquid-based separation means. The analytes or antagonists to be detected act can act as ligands, which mean that they can bind to a specific receptor or receptors.

The method employs cell-based biosensors expressing specific receptors to serve as ligand detectors. An important feature of the invention is that the receptor, comprising the functional unit of the detector, is pre-  
5 activated by constantly including a receptor-specific agonist or modulator into the liquid-based separation means. Analytes, such as antagonists, is detected in that they modulate or inhibit the pre-activated receptor response. The use of a pre-activated or constantly acti-  
10 vated biosensor is one of the most important characteris-  
tics of the present invention.

Thus, the present invention relates to a method for detection of at least one receptor antagonist and/or at least one receptor modulator, comprising the following  
15 steps:

(I) a sample containing the receptor antagonist and/or the receptor modulator is fractionated by use of a liquid-based separation means

20 (II) a fraction containing the receptor antagonist and/or the receptor modulator is fed directly to a biosensor which is activated by an appropriate receptor agonist and, as a result of this activation, is generating a measurable response, said agonist being fed to the biosensor through the liquid-based separation means together  
25 with the antagonist

(III) the change of the response resulting from de-activation of the receptor agonist-activated biosensor by the receptor antagonist and/or the receptor modulator is measured.

30 The present invention also relates to an apparatus for detection of a receptor antagonist comprising a capillary electrophoresis separation capillary containing an electrolyte supplemented with an appropriate receptor agonist, the sample inlet part of which is connected to a high-voltage power supply through a buffer vial contain-  
35 ing a buffer supplemented with an appropriate receptor agonist and the grounded outlet part of which ends close

to a patch-clamped biosensor that is activated by the receptor agonist and deactivated by the fractionated antagonist; the apparatus further comprising a patch clamp electrode and means to record currents detected by the  
5 patch clamp electrode.

The method and the apparatus according to the present invention enables a one-step fractionation immediately followed by detection. This is a big advantage compared to known techniques which involves several separation steps.  
10

The present invention also relates to an apparatus and method for better resolution of the separated analytes or antagonists due to a periodic resensitisation of the biosensor by an interlocked pulsed flow system.

15 The methods and the apparatuses according to the invention have a variety of uses. For example, they are well-suited for drug screening since many drugs or pharmaceutically active components are receptor antagonists or receptor modulators, but they can also be used for applications in other areas such as environmental, food,  
20 and cosmetic industries.

When the method or the apparatus according to the invention is used for screening of antagonists or drugs they provide a number of advantages over methods according to prior art. Since cell biosensors of the type described herein by themselves are not particularly useful at identifying antagonists or drugs acting as inhibitors in a mixture of antagonists or drugs, it is a great advantage to use the method according to which they are  
25 pre-activated by a selective agonist which is incorporated into the running buffer in the liquid-based separation means. An advantage of this system is that the state of the biosensor, that is the degree of receptor activation, is known through this continuous activation by an  
30 agonist. An another significant advantage of the present invention is that long-time exposure of the cell by agonist or antagonist can be avoided by displacement of the  
35

cell from the outlet of the liquid-based separation means. This is in contrast to keeping the concentration of the agonist at a high level in the buffer solution in the Petri-dish, as described in the above mentioned patent application PCT/US95/12444. The fact that the agonist according to the present invention is present in the liquid-based separation means where the separation of the antagonist takes place provides a very important advantage compared to the methods described in WO 96/10170 since this results in a pre-activation of the biosensor enabling accurate detection of antagonists.

The characterising features of the invention will be evident from the following description and the appended claims.

15

#### Brief descriptions of the drawings

The invention will now be described in further detail hereinafter with reference to the accompanying drawings on which:

20

Fig. 1 A-C shows, for comparison, absorbance detection, patch clamp detection and interlocked pulsed patch-clamp detection, coupled to capillary electrophoresis.

25

Fig 1 A shows the separation and detection of analyte 1 and analyte 2, with similar migration times, by absorbance detection in capillary electrophoresis. The recorded trace gives gaussian distributed and overlapping peaks.

30

Fig 1 B shows capillary electrophoresis-patch clamp detection of the same separation of analyte 1 and analyte 2, as in Fig. 1 A. Notable is that only analyte 1 is detected due to desensitisation. Fig 1 C shows a theoretical prediction of that repeated resensitisation of the detector by interlocked pulsing gives an increased resolution in CE-PC detection of analyte 1 and analyte 2.

35

Fig. 2 shows a preferred embodiment of the apparatus according to the invention, namely a capillary electrophoresis-patch clamp detection system.

5 Fig. 3 A-B shows an enlarged part of the capillary electrophoresis-patch clamp detection system according to figure 2.

10 Fig 3 A shows the electrophoresis capillary. The capillary, into which a receptor antagonist has been injected, is filled with a receptor agonist-supplemented buffer and its flow is directed onto the surface of a patch-clamped cell.

15 Fig 3 B shows the same capillary and the same patch-clamped cell at a later point of time when the receptor antagonists have migrated through the entire length of the capillary and started to antagonise the binding of receptor agonists.

Fig. 4 A - B show a model of a device constructed for switching between superfusion and electrophoresis.

20 Fig. A shows the device consisting of two fused-silica capillaries which are mounted in parallel. The cell, which is attached to the patch clamp electrode, is placed in front of one of the two capillaries by a micromanipulator.

25 Fig. 4 B illustrates how the receptors at the cell-surface are resensitised due to superfusion of the cell by a physiological buffer when the cell is in position one.

30 Fig. 4 C illustrates how electrophoretically separated analytes are detected by means of patch-clamp when the cell is in position two.

35 Fig. 5 A and B show a schematic drawing presenting a second strategy for resensitisation of a receptor system used in patch clamp detection. This superfusion system comprises a micropipette which is placed close to the cell in the vicinity of the electrophoresis capillary outlet. A buffer flow from the micropipette is applied leading to wash-

5

ing of the analytes from the surface of the patch-clamped cell. Dissociation of the analytes from the receptors makes the cell detector resensitized. When the buffer flow is interrupted the electrophoretically separated analytes are able to bind to the receptors at the cell surface and an ion-channel mediated current is recorded by the patch-clamp amplifier system.

Fig. 6 A-C shows electropherograms illustrating controls and detection of  $Mg^{2+}$  ions.

Fig. 6 A illustrates a control trace showing activation of NMDA receptors by NMDA and glycine, Fig. 6 B illustrates a blocked response of the NMDA receptor-mediated current by separated  $Mg^{2+}$  ions.

Fig. 6 C shows a control-trace presenting the unaffected NMDA receptor response after injection of HEPES-saline containing NMDA and glycine.

Fig. 7 shows current-to-voltage relationships obtained during constant activation of the NMDA receptor and during the attenuation of this response by separated  $Mg^{2+}$  ions.

Fig. 8 shows an electropherogram illustrating patch clamp detection in capillary electrophoresis of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 6,7-dichloro-3-hydroxy-2-quinoxaline-carboxylic acid (DCQXC).

#### Detailed description of the invention

30 Below are definitions and explanations of several terms used in the description and in the appended claims.

The term "liquid-based separation means" refers to any method or apparatus for separation of a mixture of analytes or antagonists that are dissolved in a physiologically buffer, solution or any other liquid. Examples could be variations of capillary electrophoresis, such as capillary zone electrophoresis, capillary gel electro-

phoresis, micellar electrokinetic capillary electrochromatography, capillary isoelectric focusing, capillary isotachophoresis, and affinity capillary electrophoresis, as well as variations of micro liquid chromatography, such  
5 as open tube liquid chromatography.

The term "cell-based biosensor" refers to an intact cell, a part of an intact cell (such as a membrane patch), or a cell in electrical communication with a patch-clamp glass-electrode or another material, a patch  
10 or piece of a cell-membrane which is in electrical communication with a solid material as, for example, a glass-capillary, plastic or silicon surface or anything related.

The term "target molecule" refers to a macromolecule  
15 composed of a protein, glycoconjugates or lipids, which interact or binds to a ligand, analyte, an antigen or anything related. A target molecule can be a receptor, an antibody, an enzyme, or anything related. The binding of an analyte, ligand or antigen may trigger a physiological  
20 relevant process which signals the ligand or the analytes biological activity. A target molecule may be associated to an artificial or a natural lipid mono- or bilayer membrane, such as a plasma membrane, mitochondrie membrane or golgi membrane.

The term "receptor" refers to a macromolecule capable of specifically interacting with a ligand molecule. Receptors may be associated with lipid bilayer membranes, such as the extracellular, golgi or nuclear membranes, and/or be present as free or associated molecules in the  
30 cell's cytoplasm. Further, receptors may be either native to the cell biosensor, i.e. normally expressed by the cell from which the cellbiosensor is derived, or recombinant, i.e. expressed in transfected cells or xenopus oocytes.

The term "ligand" refers to a molecule which binds to a receptor which either becomes activated or inactivated. Ligands can act on the receptor as agonists or an-

tagonists or by modulating the response of the receptor by other agonists or antagonists. Binding of the ligand to the receptor is typically characterised by a high binding affinity.

5 As used in the description below and in the claims, the term "receptor antagonist" relates to receptor antagonists as well as to receptor modulators. Below, the term antagonist is used in the singular form, but the invention is of course also applicable to mixtures of different antagonists and/or receptor modulators.  
10

To decrease the time needed for screening and to minimise the number of purification steps, screening of receptor antagonists and receptor modulators using biosensors, which include target molecules (i.e. receptors),  
15 is according to the present invention coupled, preferably on-line, to a miniaturised liquid-based separation technique. This combination of a separation technique and an on-line biosensor is based on a highly efficient one-at-a-time receptor antagonist delivery to the biosensor for  
20 functional detection.

The miniaturised liquid-based separation means used according to the present invention are suitable for separating ligand analytes in picolitre and nanolitre volumes. Preferably, the miniaturised liquid-based separation means used is capillary electrophoresis. The capillary electrophoresis can e.g. be any different mode of capillary electrophoresis known in the art, such as capillary zone electrophoresis, CZE (see e.g. Jorgenson, J. W., Trends Anal. Chem. 3:51, 1984, and Altria, K., et al., Anal. Proc. 23:453, 1986), capillary gel electrophoresis, CGE (see e.g. Hjertén, S., et al., J. Chromatogr. 327:157, 1985; Hjertén, S., et al., Protides Biol. Fluids 33:537, 1985; Cohen, A. S., et al., Chromatographia 24:14, 1987; and Cohen, A. S., et al., J. Chromatogr. 397:409,  
30 1987), micellar electrokinetic capillary electrochromatography, MECC (see e.g. Terabe, S., et al., Anal. Chem. 61:251, 1989, and Tsuda, T., et al., J. Chromatogr.  
35 85:251, 1991).

248:241, 1982), capillary electrochromatography, CEC (see e.g. Knox, J. H., Chromatographia 26:329, 1988, and Jorgenson, J. W., et al., J. High Resolut. Chromatogr. Chromatogr. Commun. 8:407, 1985), capillary isotachophoresis,  
5 CIPT (see e.g. Everaerts, F. M., et al, Isotachophoresis: Theory. Instrumentation. and Application, Elsevier, Amsterdam, 1976, and Bocek, P., et al., Anal. Isotachophoresis, VCH Verlagsgesellschaft, Weinheim, 1988), or affinity capillary electrophoresis, ACE (see e.g. Chu, Y-H,  
10 et al., J. Med. Chem. 35:2915, 1992; Avila, L. Z., et al., J. Med. Chem. 36:126, 1993; and Gomez, F. A., et al., Anal. Chem. 66:1785, 1994).

In its simplest and most common embodiment capillary electrophoresis is a miniaturised separation technique  
15 that fractionates chemical species on the basis of differences in their ratios of electrical charge-to-frictional drag in a solution. Since different molecules have different charge-to-frictional drag ratios, separated components migrate at characteristic rates, making  
20 identification possible. With capillary electrophoresis it is possible to separate complex chemical mixtures with high efficiency (up to  $10^6$  theoretical plates) in typically less than 20 minutes. Since capillary electrophoresis handles samples down to  $10^{-18}$  litre, it is well suited  
25 for micro- and nanotechnology applications.

In its simplest and most common embodiment, a capillary electrophoresis system consists of a narrow-bore (inner diameter 5-75  $\mu\text{m}$  fused-silica capillary (usually with a length of 20 to 100 cm) filled with an electrolyte  
30 solution. The ends of the capillary are placed in electrolyte-containing reservoirs having either a cathode or an anode connected to a high-voltage source. When an electrical field is applied across the solution-filled fused silica capillary, a layer of mobile charge that accumulates along the counter-charged fused silica surface induces electroosmosis (bulk solution flow). Under typical operating conditions for capillary electrophoresis  
35

this sheath of ions is positively charged, and consequently, drags bulk solution from the anode to the cathode. A practical result of electroosmosis flow is that during a separation in free-solution capillary electrophoresis, all species - whether possessing positive, neutral, or negative charge - can be made to migrate in the same direction past a single detector.

The biosensor used according to the present invention is preferably an eukaryotic or a prokaryotic cell containing specific receptors, a confluent layer of such cells, a part of a cell membrane containing specific receptors or a cluster of cells containing specific receptors. It is also possible to use a detector based on receptors inserted into or on liposomes, lipid films or other materials as a plastic surface or any related material.

The cells used for the biosensor, including a target molecule or a recombinantly expressed target protein, preferably a receptor, can be human, bacterial and/or yeast cells. Mammalian tissue cultured cells such as Chinese hamster ovary (CHO) cells, NIH-3T3 and HEK-293 cells, for example, are especially advantageous as cell-based biosensors expressing recombinant target molecules, in that they provide an environment that is similar to the milieu of the natural human cells (see e.g. Beohar, N., et al., J. Biol. Chem. 273:9168, 1998; Park, K., et al., J. Membr. Biol. 163:87, 1998; and Hirst, R. A., et al., J. Neurochem. 70:2273, 1998). To a great degree permeability, post-translational processing, signalling and coupling to other cellular factors in these cells are similar to these processes in most mammalian cells.

Another cell-system frequently used for expression of recombinant proteins is yeast (see e.g. Li, Z., et al., Eur. J. Biochem. 252:391, 1998). Yeast cells offer a number of advantages; they are well characterised, they are easy to manipulate genetically and fast growing. It has also been shown that they contain the machinery for

post-translational modification and they possess intracellular signalling systems.

Furthermore, Gurdon and colleagues (see Gurdon, J. B., et al., Nature 233:177, 1971) opened a broad spectrum of possibilities for the study of the function of proteins by demonstrating the ability of *Xenopus* laevis oocytes to synthesise exogenous proteins when injected with mRNA. The oocyte-model is a particularly attractive approach to the investigation of the structure-function relations of membrane proteins. Consequently, expression of functional receptors for neurotransmitters and ion-channels were demonstrated in oocytes in the beginning of the 1980s (see Sumikawa, K., et al., Nature, London 292:862, 1981, and Barnard, E. A., et al., Proc. R. Soc. London Ser. B 215:241, 1982).

Thus, living cells used as biosensors are particularly advantageous because of the physiological and functional information which can be extracted from a receptor-induced response.

As stated above, the present invention involves the use of receptor agonists making it possible to detect receptor antagonists. Nearly all cells possess on their surface a wide range of various receptors specific for appropriate agonists as well as antagonists. When binding a specific agonist, the receptor is activated and undergo a conformational change which triggers a cellular response.

These receptors have evolved their specificity during billions of years, which makes them very suitable as highly specific functional units in biosensors. Glutamate receptors, for example, play a crucial role in neurotransmission, the formation of neuronal circuits, in synaptogenesis and synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD). Excessive activation of glutamate receptors is also thought to contribute to the neurodegeneration which takes place in a wide range of neurological insults such as brain ische-

mia (see e.g. Beneviste, H., et al., J. Neurochem. 43:1369, 1984, and Hagberg, H., et al., J. Cereb. Blood Flow Metab. 5:413, 1985) and epilepsy (see e.g. Aram, J. A., et al., J. Pharmacol. Exp. Ther. 248:320, 1989; Yeh, G. C., et al., Proc. Natl. Acad. Sci USA 86:8157, 1989; and Hosford, D. A., et al., Soc. Neurosci. Abstr. 15:1163, 1989).

The roles of glutamate receptors are strongly coupled to their ion-permeability properties, both in the normal and dysfunctional brain. Their selective permeability to  $\text{Na}^+$ ,  $\text{K}^+$  and  $\text{Ca}^{2+}$ , makes them mediators of synaptic transmission in many neurons of the central nervous system (CNS). A key event in glutamate induced cell death, for example, is increased intracellular  $\text{Ca}^{2+}$  which generates free radicals and endonucleases (see e.g. Siesjö, B. K., et al., J. Cereb. Blood Flow Metab. 9:127, 1989, and Coyle, J. T., et al., Science 262:689, 1993) as well as transcriptional activation of specific "cell death". Thus naturally expressed receptors, as for example glutamate receptors, constitute excellent and selective detectors for detection and discovering of endogenous drug candidates, which may modulate or inhibit a wide range of receptor systems involved in the development of various diseases.

Bacteria such as *Escherichia coli*, *Bacillus* sp. and *Staphylococcus aureus* as well as yeast such as *Saccharomyces cerevisiae* provide alternative expression systems for cloned recombinant mammalian genes as well as microbial targets. Bacteria are genetically well characterised, have a short generation time, are easy to manipulate and inexpensive to grow. Thus these amplification systems provides a means of producing sufficient material of cDNA expressing a specific protein, which can be used in production of mRNA for injection in *Xenopus* oocytes or for transfection into mammalian tissue cultured cells.

The advantage with expressing recombinant genes in a cell-based biosensor used according to the invention is

that the receptors in any of the cell- or cell membrane-based biosensors can be of any kind, e.g. ligand-gated ion channels, metabotropic, hematopoetic, tyrosine-kinase-coupled etc. Biosensors, expressing recombinant 5 receptors, can also be designed to be sensitive to drugs which may inhibit or modulate the development of a disease. This sensitivity of the biosensor will be governed by the role of a specific recombinant receptor in disease development. Thus, the choice of the biosensor is based 10 on the receptor antagonist one wishes to screen. For example, it is possible to use liver cells in order to study receptor antagonists used in pharmaceuticals meant to affect the liver.

15 Since the receptor antagonist to be detected binds to the biosensor, e.g. containing cell receptors, without eliciting a response, the biosensor system needs to be activated, preferably constantly and preferably by a receptor agonist, in order to enable detection. The activation caused by the receptor agonist is changed, normally decreased, by the receptor antagonist and this change of 20 the response is detectable.

As stated above, the biosensor is either pre-activated or constantly activated by use of a receptor 25 agonist. This receptor agonist is preferably included in the buffer solution in the liquid-based separation means.

The detection of the response generated by the activated biosensor and of the change of the response caused by the receptor antagonist to be detected are made by an 30 appropriate technique depending on the type of the generated response. The response can e.g. be a transmembrane current measured by patch clamp or two-electrode voltage clamp, it can be fluorescence from voltage-sensitive dyes or it can be fluorescence from calcium-chelated fluorophores, such as Fura and Fluo-3 (a  $\text{Ca}^{2+}$  chelating dye), 35 which are included in measurements of intracellular calcium coupled to activation of metabotropic receptors in

the cell membrane. The preferred detection technique according to the invention is patch clamp detection, and the generated response measurable is thus an electrical current.

5 Katz and Thesleff discovered that the macroscopic endplate conductance falls within a few seconds when acetylcholine (ACh) is added to an endplate (see Katz, B., and Thesleff, S., J. Physiol., London, 138:63, 1957). This process is called desensitisation. Desensitised  
10 channels were unresponsive to added ACh and recover their sensitivity only some seconds or even minutes after the removal of ACh. Generally, a broad range ligand-receptor interactions at cell surfaces, which triggers cell responses with varying characteristics, i.e. increased con-  
15 ductance across the cell membrane, activation of G- protein coupled intracellular cascade processes, phosphorylation of proteins or triggering of intracellular modulations of transcription, desensitise. Such receptor properties may cause problems in detecting antagonists  
20 with similar electrophoretic migration times when biological samples are separated and detected by the CE-PC technique, where the receptor systems comprises the functional unit in the detector.

If two analytes (analyte 1 and analyte 2), as for  
25 example glutamate and aspartate, with similar migration times are separated and detected by a conventional detector such as an absorbance detector, the recorded trace will give gaussian distributed and overlapping peaks, as illustrated in figure 1 A where the separation and detec-  
30 tion of analyte 1 and analyte 2, with similar migration times, by absorbance detection in capillary electrophoresis is shown. Even if the responses are improperly re- solved, the trace gives information about two existing compounds in the sample. However, if the same sample is  
35 separated by the CE-PC technique, analyte 2 will not be detected when both analytes activate the same desensitising receptor system. The receptor population

will be activated and desensitised by analyte 1 before analyte 2 reaches the receptor surface leading to a single response in the capillary electropherogram, as illustrated in figure 1 B, where capillary electrophoresis-patch clamp detection of the same separation of analyte 1 and analyte 2 as in figure 1 A is shown. Notable is that just analyte 1 is detected due to desensitisation. A solution to this problem involves pulsed resensitisation of the environment surrounding the receptors at a specific frequency due to repeated dissociation of the eluting analytes from the binding site of the receptor. The reactivation of the receptor population enables the analytes to repeatedly give desensitised responses which will be presented with a gaussian distribution, as illustrated in figure 1 C., where a theoretical prediction of that repeated pulsing gives an increased resolution in CE-PC detection of analyte 1 and analyte 2 is shown. This will also improve the quantitative abilities of the technique.

Below, preferred embodiments of the present invention will be described.

According to the first preferred embodiment the miniaturised separation technique is capillary electrophoresis and the biosensor is a patch-clamped cell or part of a cell membrane, and the detection means are thus a patch clamp electrode.

According to the patch clamp technique, a cell or part of a glass micropipette, or a patch clamp electrode, and a patch clamp electrode, or a patch clamp electrode, and manipulated to yield one of several desired configurations, i.e., outside-out, inside-out, or whole-cell recording modes. The outside-out and inside-out configurations refer to the word "patch", that is a small piece of a cell membrane which is attached to the tip of an electrode for recording of single ion-channel currents (see e.g. Hamill, O. P., et al., Pflug. Arch. 391:85, 1981).

The patch clamp technique utilises in its simplest embodiment a highly sensitive feedback current-to-voltage converter, which has the ability to measure sub-picoampere currents. The measuring principle of patch clamp 5 relies on the fact that the ionic flow across a cell membrane can be measured as an electrical current if the membrane potential is held constant, typically for neuronal cells in the range -30 to -90 mV.

There are three main reasons to use the patch clamp 10 technique to measure small currents crossing the cell-membrane:

- (1) Clamping the voltage eliminates the capacitive current, except for a brief time following a step to a new voltage.
- 15 (2) Except for the brief charging time, the currents that flow are proportional only to the membrane conductance, i.e. to the number of open ion-channels.
- (3) If ion-channel gating is determined by the transmembrane voltage alone, voltage clamp offers control over 20 the key variable that determines the opening and closing of ion channels.

A preferred embodiment of the apparatus according to the present invention is shown in figure 2. The inlet end, i.e. the sample injection end, of a fused silica 25 capillary electrophoresis separation capillary 1 is connected to a high-voltage power supply 2, preferably a positive high-voltage power supply, through a buffer vial 3. The buffer vial 3 is preferably housed in a polycarbonate holder equipped with a safety interlock to prevent 30 electric shock. The capillary is grounded, e.g. approximately 5 cm above the outlet 4. The grounding can be accomplished by use of another buffer vial 5. The outlet 4 of the capillary 1 is positioned in a cell bath 6. The cell bath 6 contains the same media as the one used as 35 electrolyte in the capillary electrophoresis capillary 1 with one exception - the media in the electrophoresis capillary 1 also comprises agonists which is lacking in

the media in the cell bath. The same media as used in the cell bath is also used in the inlet buffer vial 3 and in the buffer vial 5. The use of only one media enables avoiding liquid junction potentials. The tip 7 of the 5 patch clamp electrode 8 holding the patch-clamped cell 9 is preferably positioned approximately 5 - 25  $\mu\text{m}$  from the capillary outlet 4 by means of at least one micropositioner 10, 11 controlling the capillary and/or the patch clamp electrode. According to one embodiment, the whole 10 system is placed in a Faraday cage (not shown). The patch clamp electrode is connected to a I-V-converter 12. In order to facilitate positioning of the capillary and the patch clamp electrode holding the cell, the cell bath is preferably placed on a microscope objective 13.

15 The function of the biosensor, in this case a patch-clamped cell, is illustrated in figure 3 A and 3 B.

The capillary electrophoresis capillary 1 in figure 3 A is filled with a receptor agonist-supplemented buffer with its flow directed onto the surface of a patch-clamped cell 9. The receptor agonists, shown in figure 20 3 A and 3 B as unfilled stars, continuously activate the ligand-gated ion channels 19 in the cell membrane 20 which, in this case, are permeable to sodium ions. Thus, when the receptor agonists bind to the receptors the so- 25 dium channels open and sodium ions diffuse from the outside of the cell into the cytoplasm. This flux of ions can be measured with the patch clamp electrode 8, preferably an Ag/AgCl-electrode, connected to a patch clamp amplifier, as an inward current, provided that the cell 30 membrane is kept at a constant potential. In the capillary 1 there are also receptor antagonists, shown in figure 3 A and 3 B as filled tailed stars, i.e. the compound that are to be screened, which have been injected into the capillary 1 and have migrated a distance proportional 35 to the charge-to-friction drag ratio of the receptor antagonist and the applied field strength.

In figure 3 B the receptor antagonists have migrated through the entire length of the capillary electrophoresis capillary 1 and started to antagonise the binding of receptor agonists. When the receptor antagonists bind to 5 the receptors, the sodium permeable ion channel close and the inward transmembrane currents decrease. This decreased current is detected with the patch clamp electrode 8.

According to this preferred embodiment of the invention 10 the receptors in the cell membrane are constantly activated by bathing of the cells in a solution containing specific receptor agonists. Preferably the separation technique used, in this case capillary electrophoresis, both deliver the receptor agonists and fractionates the 15 receptor antagonists.

Thus, this preferred embodiment of the invention can be used for detection of any natural and synthetic receptor 20 antagonists or receptor modulators that inhibit or negatively modulate receptor/ion-channel functions and effectively decrease receptor agonist-evoked membrane currents. This preferred embodiment of the invention thus offers possibilities to identify endogenous and synthetic receptor antagonists and to determine their mode of action 25 on any ionotropic receptor system.

Another advantage of this preferred embodiment of the invention is that when ionotropic receptors are used in the capillary electrophoresis-patch clamp system, it is possible to gain full recovery of the detection system 30 in milliseconds after the bioactive molecule has been washed away from the cell.

Another preferred embodiment of the present invention relates to pre-activation of desensitising detector systems coupled to interlocked-pulsed superfusion, i.e. 35 interlocked superfusion of the desensitised biosensor is used to resensitised the biosensor. This can be performed by pulsing the activation of the biosensor by delivery of the receptor agonist to the biosensor for short period of

times, said periods being separated by other periods when no agonist is delivered to the biosensor, which is further described below.

According to the present invention it is thus possible to improve the resolution of the detected bioactive analytes by using a method or apparatus according to which a pulsed flow of a buffer solution washes an area around the biosensor constituting the detector which is coupled to a separation system. Practically, this can be performed in two ways, as illustrated in figures 4 A -C, and figure 5, respectively.

The strategy illustrated in figures 4 A - C involves two capillaries. One of the capillary 1 is used for electrophoretic separations and for delivery of the agonist to the biosensor, and the other capillary 14 is used for delivery of buffer, for rinsing of the biosensor, in front of the capillary outlet. A means 15 fixes the capillaries 1, 14 parallelly together. The position of the capillaries fixed together is controlled by a micromanipulator 10. In this system a switching mode places the patch-clamped cell 9 either at the outlet of the capillary 14 coupled to the superfusion system 16 - position one - or at the outlet of the electrophoresis capillary 1 - position two, as illustrated in figures 4 B and 4 C. In figure 4 B the situation when the cell is placed in position one is illustrated. In this position the receptors at the cell-surface are resensitised due to superfusion of the cell by a physiological compatible buffer when the cell is position one. In figure 4 C the situation when the cell is placed in position two is illustrated. In this position the electrophoretically separated analytes are detected by means of patch-clamp. Thus by shifting the capillaries at a specific frequency a train of desensitised responses is attained, an example of which is illustrated in figure 1 C.

A second strategy is illustrated in figures 5 A and 5 B. This set up involves a superfusion system comprising

a glass micropipette 17 which is placed close to the cell 9 in the vicinity of the capillary outlet 4. The buffer flow applied from the glass-micropipette 17 leads to washing of the analytes from the surface of the patch-clamped cell 9, as shown in figure 5 A. The dissociation of the analytes from the receptors makes the cell detector resensitised. When the buffer flow is interrupted, as shown in figure 5 B, the electrophoretically separated analytes are able to bind to the receptors at the cell surface and an ion-channel mediated current is recorded by the patch-clamp amplifier system. The buffer flow from the pipette 17 is pulsed at a specific frequency by a external device (not shown in the figure) thereby reactiving the receptors for detection. The pulsing device can be any appropriate device known to persons skilled in the art (see e.g. Smart, T. G., J. Physiol. 447:587, 1992).

#### Examples

These examples are intended to further illustrate the invention and should in no way be considered to limit 5 the scope of the invention.

In the examples below the following materials and methods were used.

*Biosensor-compatible buffers:* Separation of mixtures of glutamate receptor antagonists were performed using 10 cell-based biosensor-compatible buffers. A cell-based biosensor-compatible buffer is a buffer which effectively keeps the cell-based biosensor in a functional and viable condition during the course of the experiment or the analysis procedure.

15 A slightly modified standard HEPES-saline buffer containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 10 mM glucose and 10 mM HEPES (pH 7.4, NaOH) was used as extracellular and capillary buffer in examples 1 and 2 except in the separation of Mg<sup>2+</sup> where MgCl<sub>2</sub> were omitted.

As described in the examples, the preferred agonist were only included in the capillary solution.

Acute isolation of neurons from the olfactory bulb of the rat: The cells used were interneurons from rat olfactory bulb acutely isolated according to the procedures described by Jacobson et al. (see Jacobson, I., Neurosci. Res. Comm. 8:11, 1991, and Jacobson, I., et al., Neurosci. Res. Comm. 10:177, 1992).

Newborn or adult rats (10-200 g) were anaesthetised with halothane (ISC Chemicals Ltd., Avonmouth, England) and decapitated. The olfactory bulbs were dissected and sliced into four pieces and placed in an incubation chamber. the chamber contained proteases from Aspergillus oryzae (2.5 mg/ml) which were dissolved in pre-warmed (32°C) HEPES-saline buffer (see above). After 25-30 min., the slices were washed with the same buffer solution for 20 min. The solutions were constantly perfused with 95% O<sub>2</sub> and 5% CO<sub>2</sub> during both the enzymatic treatment and the washing. The slices were then kept at 20°C in a HEPES-saline buffer containing 1 mM CaCl<sub>2</sub>, and bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. The slices were then disintegrated by shear forces by gentle suction through the tip of a firepolished Pasteur pipette. The cell suspension was then placed in a Petri dish and diluted with a Ca<sup>2+</sup>-containing (1 mM) HEPES-saline buffer. The Petri dish was transferred to the microscope stage. Viable interneurons were harvested up to six hours after the interruption of the enzymatic treatment. Chemicals and enzymes were obtained from Sigma (St Louis, MO, USA).

Capillary electrophoresis: The capillary electrophoresis separations were performed in fused silica capillaries (length: 25-50 cm, inner diameter: 50 µm) from Polymicro Tech., Phoenix, AZ, USA. The electrophoresis was performed by applying a positive potential of 12 kV to the inlet of the capillary by a high voltage supply, manufactured by LKB, Bromma, Sweden. Since the high voltages produce electrical field strengths of several hun-

dred volts per centimetre,. the outlet of the capillary was fractured and grounded 5 cm above the outlet to create an almost field free region at the position of the cell detector. The injections were made hydrodynamically 5 by placing the capillary inlet in sample solution 20 cm above the outlet end for 10 sec.

*Patch-clamp detection:* The patch clamp detection was performed in the whole-cell configuration as described by Hamill, et al. (see Hamill, O. P., et al, Pflug. Arch. 10 391:85, 1981). The tip of the patch clamp electrode was placed 5-25  $\mu\text{m}$  from the centre of the capillary outlet. Patch pipettes were fabricated from thick-walled boro-silicate glass (code no GC150-10, Clark Electromedical Instruments, Pangbourne, Reading, UK). The diameters and 15 the resistances of the tips were about 2-5  $\mu\text{m}$  and 5-15  $\text{M}\Omega$ , respectively. The estimated series resistance was always less than 50  $\text{M}\Omega$ . The experiments were performed at room temperature of 18-22°C. The electrodes (reference 20 and patch electrodes), contained a solution of 100 mM KF, 2 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 11 mM EGTA, 10 mM HEPES; the pH was adjusted to 7.2 with KOH.

The signals were recorded with a patch clamp amplifier (Model List L/M EPC-7, List-Electronic, Darmstadt, Germany), digitised (20 kHz, PCM 2 A/D VCR adapter, Medical Systems Corp., NY, USA), and stored on videotape. For 25 the production of electropherograms the signals from the videotape were digitised at 2 Hz.

It is of outmost importance to sample the signals at proper rates for gaining complete information.

For spectral analysis of whole-cell currents (see 30 Colquhoun, D., et al., Proc. R. Soc. Lond. B. Biol. Sci. 199:231, 1981) the signal from the videoadaptor was filtered with an 8 pole Butterworth filter (bandwith 3 kHz) and digitised at 6 Hz. Records were divided into 0.7 s 35 blocks prior to calculation of the spectral density and the mean power spectrum was calculated by averaging all power spectra obtained from these blocks (at least 20).

WO 98/55870

21

The receptor agonist-induced power spectra were subtracted from power spectra obtained during membrane resting conditions. The resulting power spectra were fitted by a double Lorentzian function using a least-squares Levenberg-Marquardt algorithm with proportional weighting.

The relationships between the current and the voltage ( $I-V$ ) were obtained from current responses evoked by continuous perfusion of receptor agonist, and from blocked receptor antagonist. The holding potential was changed by using a voltage ramp (-80 to +40 mV, duration 3 to 1 s, pClamp software, Axon Instruments; Foster City, CA, USA). For elimination of responses evoked by voltage-dependent ion channels, the  $I-V$  curve obtained between the receptor agonist- or receptor antagonist-activated responses were subtracted from the ramp obtained during the responses.

Example 1 - separation and detection of  $Mg^{2+}$   
In this example  $Mg^{2+}$  ions, that reversibly block the N-methyl-D-aspartate receptor in a voltage-dependent manner, were separated and detected by the patch-clamped cells.

The N-methyl-D-aspartate receptors on the cells were activated by N-methyl-D-aspartate (agonist) and glycine (co-agonist), continuously delivered from the electrophoresis capillary.

The electrolyte in the capillary electrophoresis a  $Mg^{2+}$ -free HEPES-saline containing 200  $\mu M$  N-methyl-D-aspartate (NMDA) and 20  $\mu M$  glycine. The same buffer was used in the cell bath, but without NMDA and glycine. In figure 6 A there is a control trace showing activation of NMDA receptors by NMDA (200  $\mu M$ ) and glycine (20  $\mu M$ ), delivered to the cell through the capillary electro-

phoresis capillary. The response occurs immediately following the start of the electrophoresis.

Mg<sup>2+</sup> ions (2 mM) hydrodynamically injected into the electrophoresis capillary migrate through the capillary 5 in less than a minute and are detected as a transient Gaussian-distributed attenuation of N-methyl-D-aspartate-activated current responses at a holding potential of -70 mV.

This is illustrated in figure 6 B by an electro-10 pherogram showing a blocked response of the NMDA receptor mediated current by separated Mg<sup>2+</sup> ions migrating at approximately 20 s. The response is fitted to a Gaussian function.

In figure 6 C there is a control trace presenting 15 the unaffected NMDA receptor response after injection of HEPES-saline containing 200 µM NMDA and 20 µM glycine.

The current-to-voltage relationships obtained during constant activation of the NMDA receptor and during the attenuation of this response by separated Mg<sup>2+</sup> ions are 20 shown in figure 5. The relationships display the characteristic features, i.e. blockade of inward currents at membrane resting potentials and unaltered outward currents at positive potentials. The current-to-voltage relationship for the NMDA receptor by activation of NMDA in 25 Mg<sup>2+</sup>-free media is represented by open squares, and in Mg<sup>2+</sup>-containing media by filled diamonds. The plot in figure 7 is based on averages of three normalised current amplitudes at each decade (from -80 mV to +40 mV).

30 Example 2 - separation and detection of 6-cyano-7-nitro-  
quinoxaline-2,3-dione and 6,7-dichloro-3-hydroxy-2-  
quinoxaline-carboxylic acid

Since glutamate receptors are implicated in a wide range of diseases in the central nervous system (CNS) of 35 mammals, including Alzheimer's disease and Parkinson's disease, and CNS dysfunctional processes such as epilepsy and neuronal death due to mechanical trauma and stroke,

6-cyano-7-nitroquinoxaline-2,3-dione and its analogues can be useful as drugs protecting against such diseases and disorders (see Honore, T., et al., *Science* 241: 701 (1988)).

5        6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 6,7-dichloro-3-hydroxy-2-quinoxaline-carboxylic acid (DCQXC), both which reversibly block  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and kainate (KA) receptors, belonging to the glutamate receptor superfamily, were  
10 separated by capillary electrophoresis and detected on-line by patch-clamped cells.

The electrolyte in the capillary electrophoresis capillary, the medium in the cell bath and the buffer used in this example are the same as used in example 1,  
15 with the exception that the agonist in this example was kainate instead of NMDA and glycine.

Non-desensitising AMPA receptors were activated by 100  $\mu$ M KA (agonist) continuously delivered from the electrophoresis capillary.

20        At a holding potential of -70 mV CNQX and DCQXC were detected at characteristic migration times as transient attenuations of KA-activated current responses. This is shown in figure 8.

CLAIMS

1. A method for detection of a receptor antagonist or a receptor modulator, characterised in that it comprises the following steps:

5 (I) a sample containing the receptor antagonist or modulator is fractionated by use of a liquid-based separation means

10 (II) a fraction containing the receptor antagonist or modulator is fed directly to a biosensor (9) which is activated by an appropriate receptor agonist and, as a result of this activation, is generating a measurable response, said agonist being fed to the biosensor through the liquid-based separation means together with the antagonist or modulator

15 (III) the change of the response resulting from deactivation of the receptor agonist-activated biosensor (9) by the receptor antagonist or modulator is measured.

2. A method according to claim 1, wherein the fractionation in step (I) is achieved by a microcolumn separation technique.

20 3. A method according to claim 2, wherein the microcolumn separation technique is capillary electrophoresis.

4. A method according to any one of claims 1-3, wherein the response generated by the biosensor (9) is an electrical current.

25 5. A method according to claim 4, wherein the electrical current is measured by the use of a patch clamp technique or a two-electrode voltage clamp technique.

30 6. A method according to any one of claims 1-3, wherein the response generated by the biosensor (9) is fluorescence.

35 7. A method according to any one of the claims 1-6, wherein the biosensor (9) is constituted by at least one cell or part of a cell comprising at least one receptor for the agonist used and for the antagonist to be detected.

8. A method according to any one of the claims 1-7, wherein the activation of the biosensor (9) is pulsed by delivery of the receptor agonist to the biosensor for short period of times, said periods being separated by  
5 other periods when no agonist is delivered to the biosensor.

9. A method according to claim 8, wherein the response generated from the biosensor (9) is measured during the periods when no agonist is delivered to the bio-  
10 sensor.

10. A method according to any one of the claims 1-11, wherein the desensitised biosensor is resensitised by interlocked superfusion of the biosensor.

11. A method according to claim 12, wherein the in-  
15 terlocked superfusion is performed by use of a column, placed in parallel to the liquid-based separation means.

12. A method according to claim 12, wherein the in-  
terlocked superfusion is performed by use of a glass pi-  
pette placed with its outlet adjacent to the outlet of  
20 the liquid-based separation means.

13. An apparatus for detection of a receptor antago-  
nist or a receptor modulator comprising a capillary elec-  
trophoresis separation capillary (1) containing an elec-  
trolyte supplemented with an appropriate receptor ago-  
25 nist, the sample inlet part of which is connected to a  
high-voltage power supply (2) through a buffer vial (3)  
containing a buffer supplemented with an appropriate re-  
ceptor agonist and the grounded outlet part (4) of which  
ends close to a patch-clamped biosensor (9) that is acti-  
30 vated by the receptor agonist and deactivated by the  
fractionated antagonist; the apparatus further comprising  
a patch clamp electrode (8) and means to record currents  
detected by the patch clamp electrode.

14. An apparatus according to claim 13 wherein the  
35 capillary electrophoresis capillary (1) is a fused silica  
capillary.

15. An apparatus according to claim 13 or 14 further comprising at least one micropositioner (10) connected to the capillary and/or the patch clamp electrode.

16. An apparatus according to any one of the claims 5 13-15, wherein the patch-clamped biosensor (9) is placed in a cell bath (6).

17. An apparatus according to claim 16, wherein the electrolyte, the buffer and the cell bath are constituted of the same medium, with the only difference that the 10 electrolyte and the buffer but not the cell bath are supplemented with an appropriate agonist.

18. An apparatus according to any one of the claims 13-17 further comprising a second capillary (14) for delivery of a buffer not comprising any agonist, said second capillary (14) being connected to a superfusion system (16), said apparatus also comprising means (10) for switching the position of the capillaries so that the patch-clamped biosensor (9) alternatively is placed in front of the outlet of the first capillary (1) and in 20 front of the outlet of the second capillary (14).

19. An apparatus according to any one of the claims 13-17 further comprising means (17) for superfusing the patch-clamped biosensor (9) with a buffer not comprising any agonist.

25 20. An apparatus according to claim 19 further comprising means for pulsing the flow of the buffer delivered from the superfusion means.

21. A method according to claim 20, wherein said means (17) is a micropipette.

30 22. An apparatus according to any one of the claims 13-21, wherein the biosensor (9) is constituted of at least one cell or part of a cell comprising receptors for the antagonist or modulator to be detected.

1/8


A. Absorbance Detection

Fig. 1A


B. Patch-Clamp Detector

Fig. 1B


C. Interlocked Pulsed Patch Clamp Detector

Fig. 1C

2/8




Fig. 2

3/8




Fig. 3A




Fig. 3B

4/8




Fig. 4A




Fig. 4B







Fig. 4C



RESPONSE

Fig. 5B



NO RESPONSE

Fig. 5A

○ = Analyte

6/8



Fig. 6A





Fig. 6B




Time (sec)

Fig. 6C

7/8

Fig. 7



8/8




Fig. 8

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01058

## A. CLASSIFICATION OF SUBJECT MATTER

**IPC6: G01N 33/567, G01N 33/487, C12Q 1/02, C12M 1/40**  
 According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

**IPC6: C12Q, G01N**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

**SE,DK,FI,NO classes as above**

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9610170 A1 (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY), 4 April 1996 (04.04.96), See page 17 - page 23, example 4, page 48, claims 21 and 22  --	1-15
A	WO 9004645 A1 (MOLECULAR DEVICES CORPORATION), 3 May 1990 (03.05.90), See examples 19 -23 and claims  --	1-15
A	US 4906779 A (ECKARD WEBER ET AL), 6 March 1990 (06.03.90), See column 12-13  --	1-15

 Further documents are listed in the continuation of Box C. See patent family annex.

- \* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

14 Sept 1998

Date of mailing of the international search report

20 -09- 1998

Name and mailing address of the ISA/  
**Swedish Patent Office**  
**Box 5055, S-102 42 STOCKHOLM**  
 Facsimile No. + 46 8 666 02 86

Authorized officer  
**Carl-Olof Gustafsson**  
 Telephone No. + 46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01058

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9613721 A1 (NEUROSEARCH A/S), 9 May 1996 (09.05.96), See the claims --	1
A	US 5597699 A (RICHARD G. LANZARA), 28 January 1997 (28.01.97) --	1
A	WO 9420841 A1 (UNIVERSITY OF WOLLONGONG), 15 Sept 1994 (15.09.94) --	1
A	WO 9324629 A1 (NOVO NORDISK A/S), 9 December 1993 (09.12.93), See page 9, line 15-25 --	1-15
A	US 5114681 A (JOSEPH BERTONCINI ET AL), 19 May 1992 (19.05.92) -- -----	10-12

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

27/07/98

International application No.

PCT/SE 98/01058

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
<b>WO 9610170 A1 04/04/96</b>		<b>NONE</b>		
WO 9004645 A1	03/05/90	AT 121790 T		15/05/95
		CA 2001212 A		21/04/90
		DE 68922390 D,T		05/10/95
		EP 0394406 A,B		31/10/90
		SE 0394406 T3		
		JP 3502642 T		20/06/91
		US 5278048 A		11/01/94
		US 5496697 A		05/03/96
US 4906779 A	06/03/90	US 5190976 A		02/03/93
		AU 605785 B		24/01/91
		AU 7701887 A		10/02/88
		DE 3788650 D,T		16/06/94
		EP 0314690 A,B		10/05/89
		SE 0314690 T3		
		JP 2500909 T		29/03/90
		JP 2528683 B		28/08/96
		JP 2597329 B		02/04/97
		JP 8225512 A		03/09/96
		US 4709094 A		24/11/87
		US 5093525 A		03/03/92
		US 5312840 A		17/05/94
		US 5385946 A		31/01/95
		US 5478863 A		26/12/95
		US 5502255 A		26/03/96
		US 5604228 A		18/02/97
		WO 8800583 A		28/01/88
WO 9613721 A1	09/05/96	AU 2788695 A		23/05/96
		CA 2203886 A		09/05/96
		EP 0788600 A		13/08/97
US 5597699 A	28/01/97	AU 3786793 A		26/04/94
		WO 9408240 A		14/04/94
WO 9420841 A1	15/09/94	AU 6254894 A		26/09/94
		CA 2157503 A		15/09/94
		EP 0690983 A		10/01/96
		JP 8505476 T		11/06/96
		US 5403451 A		04/04/95
WO 9324629 A1	09/12/93	EP 0672135 A		20/09/95
		JP 7506970 T		03/08/95
US 5114681 A	19/05/92	AU 7794991 A		10/10/91
		WO 9114218 A		19/09/91

